Poor Ovarian Response Clinical Trial
Official title:
A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve
Assisted reproductive technology (ART), especially controlled ovarian stimulation (COS), significantly increased clinical pregnancy rates among infertile patients. However, about 9% to 24% of patients had poor ovarian response to gonadotropins (GNS) stimulation, which was called poor ovarian response (POR). In recent years, the diagnosis and treatment of patients with low fertility is the challenge for reproductive medicine. To better demonstrate the effectiveness of various interventions and distinguish the different subgroups of patients, 2016 POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) standard changed low reaction into low prognosis of patient-oriented individual strategies to obtain eggs. For patients in group 3 and group 4 classified by POSEIDON, ovarian reserve function decline, follicular development desynchrony and low numbers of oocytes obtained lead to poor prognosis. In 2020, the prognosis based on Delphi method of assisted reproductive technology to treat low crowd diagnosis expert opinion in China recommended to give these patients conventional cosine solutions such as antagonist. In the first cycle, follicle stimulating hormone (FSH) starting dose of 225 ~ 300 iu is suggested to achieve plenty of ovarian stimulation for standards and maximize the benefits of superovulation. Because of the particularity of luteal support in the antagonist regimen, it is of great clinical significance to explore the trigger mode and combination mode of luteal support in the antagonist regimen for patients with poor prognosis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03433768 -
Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response
|
N/A | |
Recruiting |
NCT05601193 -
Ovarian PRP Injection in Women With POR
|
N/A | |
Suspended |
NCT03021915 -
Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure
|
N/A | |
Completed |
NCT04013984 -
Acupuncture for Treatment of Patients With Poor Ovarian Response
|
N/A | |
Completed |
NCT03447184 -
Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
|
||
Completed |
NCT01816321 -
Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial
|
Phase 3 | |
Recruiting |
NCT04310293 -
Novel Therapy for Poor Responders Management
|
N/A | |
Completed |
NCT05703308 -
Menstrual Blood Stem Cells in Poor Ovarian Responders
|
Phase 3 | |
Terminated |
NCT00878124 -
How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome
|
N/A | |
Not yet recruiting |
NCT06089395 -
The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR)
|
Early Phase 1 | |
Completed |
NCT01732068 -
Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol
|
Phase 2 | |
Completed |
NCT01732094 -
Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders
|
Phase 2 | |
Recruiting |
NCT04024722 -
Improving in Vitro Fertilization in Women With Poor Ovarian Response
|
N/A | |
Completed |
NCT03994614 -
the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR)
|
N/A | |
Recruiting |
NCT03830697 -
A Trial Study on Acupuncture Treatment of Poor Ovarian Response
|
N/A | |
Recruiting |
NCT02801591 -
Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET
|
N/A | |
Recruiting |
NCT04273256 -
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT02993588 -
Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders
|
Phase 2/Phase 3 | |
Terminated |
NCT02418572 -
Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial
|
Phase 3 |